Below you'll find some some of Dr. Donovan's recent videos and lecture audio recordings which highlight a variety of educational topics. The purpose of these videos is to help the public as well as the medical community gain a better understanding of the biology, diagnosis and treatment of all forms of hair loss.
In the new “Commentaries in Hair Loss” series Dr Donovan takes on some important questions in the field of hair loss. This commentary addresses the key pathological findings on biopsy in androgenetic alopecia, alopecia areata and scarring alopecia.
This commentary addresses a diagnostic approach to dealing with concerns about hair loss.
In this 1 hour 15 minute video, Dr. Donovan discusses the importance of the patient history in diagnosing hair loss. Dr Donovan emphasizes that too often the information that the patient wishes to tell the physician about his or her hair loss is pushed aside in favour of the physician examining the scalp or performing various tests. Dr Donovan makes the point that the patient history is extremely important in confidently making the diagnosis of hair loss. He outlines 10 questions that must be asked of every patient with hair loss.
In this 30 minute video, Dr. Donovan discusses some emerging treatments for various types of hair loss. This includes new treatments for androgenetic alopecia, alopecia areata and chemotherapy-induced alopecia.
In this brief video, Dr. Donovan provides some key updates as they pertain to recent progress in alopecia areata research over the 2016-2018 period. The commentary focuses on 4 key areas of alopecia areata research including a) recent research research pertaining to both topical and oral janus kinase (JAK) inhibitors b) new findings regarding the role of the gastrointestinal system in alopecia areata, c) new research about the use of diphencyprone (DPCP) as a treatment for alopecia areata as well as new studies addressing the safety of outpatient (home-based) DPCP treatments and d) the role of vitamin D in alopecia areata.
This 2 hour video outlines Dr. Donovan's approach to the diagnosis and treatment of a group of hair loss conditions known as the scarring alopecia. In the first part of the video, Dr. Donovan reviews how these conditions are diagnosed and what features on a patient's history are important to arriving at a diagnosis. In the second part of the video, he reviews the distinct primary scarring alopecias including lichen planopilaris, frontal fibrosing alopecia, discoid lupus, pseudopelade, CCCA, folliculitis decalvans, dissecting cellulitis, erosive pustular dermatosis and acne keloidalis.
In this 50 minute video, Dr. Donovan provides a basic approach to the diagnosis and treatment of hair loss for family physicians. In the lecture, Dr. Donovan reviews the categorization of hair loss into the common 'non-scarring' group as well as the less common 'scarring' group. He reviews the importance of asking patients about the so called "5 S's" in diagnosing hair loss - including questions about the speed of the hair loss, sites involved, symptoms, shedding, supplements (prescription or non prescription) used.
This video provides audio for Dr. Donovan's basic science lecture on the cause of scarring alopecia. Scarring alopecia including conditions such as lichen planopilaris, frontal fibrosing alopecia, discoid lupus, folliculitis decalvans. In this lecture, Dr Donovan reviews with the audience how loss of hair follicle stems cells and destruction of stem cells are central to the underlying cause of scarring alopecia. In the last half of the video, Dr. Donovan reviews how reduction in PPAR gamma singling drives the production of toxic, 'pro-inflammatory' lipids that drive inflammation.
This video provides audio for Dr. Donovan's lecture on new research in alopecia areata in 2015-2016. Alopecia areata is an autoimmune condition affecting 2 % of the world.
This video provides an interview with Dr. Donovan following his meeting in Prague in 2012. Topics discussed include dermal cup sheath cell biology and the work of the company Replicel Life Sciences and new data with L'Oreal's Stemoxydine.